HS135, A Best-in-class Activin And GDF Ligand Trap, Is Efficacious In Experimental Left Heart Failure

Six million patients in the US have left-sided heart failure (HF), a majority of which exhibit preserved Ejection Fraction (HFpEF). Obesity is an established risk factor for the development of HF, particularly HFpEF, with an estimated 80% of HFpEF patients living with obesity. Novel treatments that address both HF pathology and obesity are thus urgently needed. Activin and growth differentiation factor (GDF) cytokines are genetically and clinically validated drivers of HF and obesity. HS135 is a novel, rationally designed Activin and GDF ligand trap with a best-in-class ligand neutralization profile to treat HF with obesity.

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Gauthier Schang, Mathilde Poujol de Molliens, Emilie Br ûlé, Ariane Sours, Cristina Chauvet, Jean-François Denis, Vannakambadi Ganesh, Ilia Tikhomirov, Gilles Tremblay, Julia Schoelermann, Maureen O'Connor-McCourt Tags: 117 Source Type: research